Diagnosis & Disease Information

Clinical Medicine Insights: Oncology

The Use of Pharmacogenomics for Selection of Therapy in Non-Small-Cell Lung Cancer

[Clinical Medicine Insights: Oncology] Performance status is the only known clinical predictor of outcome in patients with advanced non-small-cell lung cancer (NSCLC), but pharmacogenomic markers may also correlate with outcome. This study attempts to correlate clinical and pharmacogenomic measures with overall survival.

Next post in Lung Cancer